EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 37 / No 1 (Janvier 2021) Med Sci (Paris), 37 1 (2021) 53-58 References
Open Access
Issue
Med Sci (Paris)
Volume 37, Number 1, Janvier 2021
Page(s) 53 - 58
Section M/S Revues
DOI https://doi.org/10.1051/medsci/2020261
Published online 25 January 2021
  1. Drucker DJ. Advances in oral peptide therapeutics. Nat Rev Drug Disco 2020; 19 : 277–89. [CrossRef] [Google Scholar]
  2. De Nobel E, Van’t Laar A. The size of the loading dose as an important determinant of the results of the oral glucose tolerance test. A study in subjects with slightly impaired glucose tolerance. Diabetes 1978 ; 27 : 42–48. [CrossRef] [PubMed] [Google Scholar]
  3. Elrick H, Stimmler L, Hlad CJ, et al. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 1964 ; 24 : 1076–1082. [CrossRef] [PubMed] [Google Scholar]
  4. Mcintyre N, Holdsworth C, Turner D. New interpretation of oral glucose tolerance. Lancet 1964 ; 284 : 20–21. [CrossRef] [Google Scholar]
  5. Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1). Mol Metab 2019 ; 30 : 72–130. [CrossRef] [PubMed] [Google Scholar]
  6. Andersen A, Lund A, Knop FK, et al. Glucagon-like peptide 1 in health and disease. Nat Rev Endocrinol 2018 ; 14 : 390–403. [CrossRef] [PubMed] [Google Scholar]
  7. Gasbjerg LS, Bergmann NC, Stensen S, et al. Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists. Peptides 2020; 125 : 170183. [CrossRef] [PubMed] [Google Scholar]
  8. Stemmer K, Müller TD, DiMarchi RD, et al. CNS-targeting pharmacological interventions for the metabolic syndrome. J Clin Invest 2019 ; 129 : 4058–4071. [CrossRef] [PubMed] [Google Scholar]
  9. Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J 2020 ; 41 : 255–323. [CrossRef] [Google Scholar]
  10. Granhall C, Donsmark M, Blicher TM, et al. Safety and pharmacokinetics of single and multiple ascending doses of the novel oral human GLP-1 analogue, oral semaglutide, in healthy subjects and subjects with type 2 diabetes. Clin Pharmacokinet 2019 ; 58 : 781–791. [CrossRef] [PubMed] [Google Scholar]
  11. Alani AWG, Robinson JR. Mechanistic understanding of oral drug absorption enhancement of cromolyn sodium by an amino acid derivative. Pharm Res 2008 ; 25 : 48–54. [CrossRef] [PubMed] [Google Scholar]
  12. Davies M, Pieber TR, Hartoft-Nielsen ML, et al. Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with type 2 diabetes a randomized clinical trial. JAMA 2017 ; 318 : 1460–1470. [CrossRef] [PubMed] [Google Scholar]
  13. Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019 ; 381 : 841–851. [CrossRef] [Google Scholar]
  14. Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019 ; 394 : 39–50. [CrossRef] [PubMed] [Google Scholar]
  15. O’Neil PM, Birkenfeld AL, McGowan B, et al. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial. Lancet 2018 ; 392 : 637–649. [CrossRef] [PubMed] [Google Scholar]
  16. Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 2020; 8 : 392–406. [CrossRef] [PubMed] [Google Scholar]
  17. Rosenstock J, Allison D, Birkenfeld AL, et al. Effect of additional oral semaglutide vs sitagliptin on glycated hemoglobin in adults with type 2 diabetes uncontrolled with metformin alone or with sulfonylurea: The PIONEER 3 randomized clinical trial. JAMA 2019 ; 321 : 1466–1480. [CrossRef] [PubMed] [Google Scholar]
  18. Pieber TR, Bode B, Mertens A, et al. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial. Lancet Diabetes Endocrinol 2019 ; 7 : 528–539. [CrossRef] [PubMed] [Google Scholar]
  19. Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide versus empagliflozin in patients with type 2 diabetes uncontrolled on metformin: the PIONEER 2 trial. Diabetes Care 2019 ; 42 : 2272–2281. [CrossRef] [PubMed] [Google Scholar]
  20. Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability of oral semaglutide versus placebo added to insulin with or without metformin in patients with type 2 diabetes: The PIONEER 8 trial. Diabetes Care 2019 ; 42 : 2262–2271. [CrossRef] [PubMed] [Google Scholar]
  21. Hunt B, Hansen BB, Ericsson Å, et al. Evaluation of the cost per patient achieving treatment targets with oral semaglutide: a short-term cost-effectiveness analysis in the United States. Adv Ther 2019 ; 36 : 3483–3493. [CrossRef] [PubMed] [Google Scholar]
  22. Thorens B. Incrétines, sécrétion d’insuline et diabète. Med Sci (Paris) 2003 ; 19 : 860–863. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.